Our results are generated using an analytically validated process consistent with laboratory developed tests. It has not been cleared or approved by the U.S. Food and Drug Administration.

Blood Cancer Research Assays

Deep molecular profiling of blood cancers

Archer Blood Cancer research assays leverage a powerful technology for error-corrected next-generation sequencing for high sensitivity oncogene profiling.

ArcherDX Clinical Sequencing Services is performed at our wholly owned subsidiary, ArcherDX Clinical Services, Inc., which is a CLIA (Clinical Laboratory Improvements Amendment)-certified and CAP (College of American Pathologists)-accredited Clinical Services Laboratory. We offer a wide variety of services for researchers, clinicians, and life science partners.

Our results are generated using an analytically validated process consistent with laboratory developed tests. It has not been cleared or approved by the U.S. Food and Drug Administration.

Key Features

Unified
Workflow

All Archer panels are powered by Anchored Multiplex PCR (AMP™) chemistry and thus follow the same workflow for maximum lab efficiency.

Comprehensive Tumor Profiling

Get the most information from your sample - fusions, CNVs, SNVs, indels and expression levels.

Error Correction & Quantitative Analysis

Molecular barcode sequences ligated prior to amplification enable duplicate read binning and advanced error correction for confident variant calls.

Sensitive & Specific Variant Detection

Powerful bioinformatics combined with orthogonal variant verification.

Our Blood Cancer Research Assays

Archer® FusionPlex RUO panels generate target-enriched libraries from RNA to characterize gene fusions, splice variants, SNVs, indels and relative expression levels by next-generation sequencing (NGS) on Illumina® and Ion Torrent™ platforms.

Archer® FusionPlex RUO panels generate target-enriched libraries from RNA to characterize gene fusions, splice variants, SNVs, indels and relative expression levels by next-generation sequencing (NGS) on Illumina® and Ion Torrent™ platforms.

Recent publications utilizing these assay
Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples.
Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing.